A Double-Blind, Randomized, Controlled Pilot Trial of N-Acetylcysteine in Veterans With Posttraumatic Stress Disorder and Substance Use Disorders
doi:10.1177/1060028017696105 Farah GJ, Ferreira GZ, Danieletto-Zanna CF, Luppi CR, Jacomacci WP
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Weekends bring road races, tennis, climbing, cycling, pickleball, long walks across the city, and the occasional attempt to fit three different wellness appointments between brunch and dinner
148 ReygaertW
it acts on many